|Title:||Role of moxifloxacin for the treatment of commmunity-acquired complicated intra-abdominal infections in Taiwan||Authors:||Lau Y.-J.
|Issue Date:||2012||Journal Volume:||45||Journal Issue:||1||Start page/Pages:||1-6||Source:||Journal of Microbiology, Immunology and Infection||Abstract:||
Complicated intra-abdominal infections (cIAIs) are common yet serious infections that can potentially lead to substantial morbidity and morbidity. As an essential adjunct to source control, the goals of antimicrobial therapy are to promote patient recovery, reduce recurrence risk, and prevent antimicrobial resistance. The current international guidelines on the empirical treatment of community-acquired complicated IAIs were published by the Infectious Diseases Society of America (IDSA) and Surgical Infections Society (SIS) in 2010. These guidelines all recommend the use of a fluoroquinolone (ciprofloxacin or levofloxacin) plus metronidazole for mild-to-moderate- and high-severity cases. Moxifloxacin monotherapy is recommended by the current IDSA/SIS guidelines for the treatment of mild-to-moderate complicated IAIs. Moxifloxacin has demonstrated a broad spectrum coverage of both aerobic and anaerobic pathogens, good tissue penetration into the gastrointestinal tract, and a good tolerability profile. Clinical data have demonstrated that moxifloxacin is at least as effective as other standard therapeutic regimens recommended by current clinical guidelines. Due to the high rates of extended-spectrum β-lactamase (ESBL)-producing Enterobacteriaceae and fluoroquinolone-resistant Enterobacteriaceae among isolates causing community-acquired IAIs in Asia, any fluoroquinolones (including moxifloxacin) are not recommended as drugs of choice for the empirical treatment of community-acquired IAIs, particularly in countries (China, India, Thailand, and Vietnam) with fluoroquinolone resistance rates among Escherichia coli isolates of >20%. Given the low rates of fluoroquinolone-resistant (<20%) and extended-spectrum β-lactamase (ESBL)-producing (<10%) Enterobacteriaceae isolates associated community-acquired IAIs in Taiwan, it appears that moxifloxacin is considered an appropriate first-line therapy for patients with community-acquired complicated IAIs in this country. ? 2011.
|URI:||https://scholars.lib.ntu.edu.tw/handle/123456789/528483||ISSN:||1684-1182||DOI:||10.1016/j.jmii.2011.11.010||SDG/Keyword:||amoxicillin plus clavulanic acid; ceftriaxone; ciprofloxacin; ertapenem; levofloxacin; metronidazole; moxifloxacin; piperacillin plus tazobactam; abdominal infection; abscess; Acinetobacter baumannii; acute abdomen; acute appendicitis; acute cholecystitis; Aeromonas hydrophila; antibiotic resistance; antibiotic sensitivity; antibiotic therapy; antimicrobial activity; Bacteroides fragilis; cholecystitis; community acquired complicated intraabdominal infection; complicated intraabdominal infection; diverticulitis; drug bioavailability; drug efficacy; drug half life; drug safety; Enterobacter; Escherichia coli; human; Klebsiella; minimum inhibitory concentration; monotherapy; nonhuman; pathogenesis; peritonitis; phase 3 clinical trial (topic); Pseudomonas aeruginosa; randomized controlled trial (topic); review; Taiwan; time to maximum plasma concentration; unspecified side effect; Anti-Bacterial Agents; Asia; Aza Compounds; Community-Acquired Infections; Enterobacteriaceae Infections; Guidelines as Topic; Humans; Intraabdominal Infections; Quinolines; Treatment Outcome
|Appears in Collections:||醫學院附設醫院 (臺大醫院)|
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.